PeptiSystems, a biotech company from Uppsala specializing in innovative peptide and oligonucleotide drug manufacturing, has raised €3.92M (45 MSEK) in a funding round led by Sciety and Sciety Venture Partners. The investment will be used to expand production capacity, scale global sales, and enhance sustainable pharmaceutical manufacturing through its proprietary solid-phase flowthrough technology, which reduces production time by 90% and raw material usage by 70%. With revenue growth from 9.8 MSEK in 2022 to 33 MSEK in 2023 and a global client base including leading CDMOs like Corden Pharma, PeptiSystems is poised to meet increasing demand for efficient, sustainable drug production and advance its position in the precision medicine market.
While peptide and oligonucleotide drugs are transforming precision medicine by offering targeted treatments for chronic and genetic diseases, traditional manufacturing methods for peptides face significant inefficiencies. Such limitations restrict production scalability and patient access, highlighting the urgent need for innovative solutions.
PeptiSystems addresses these challenges through its proprietary solid-phase flowthrough technology. By reducing peptide production times by up to 90% and cutting raw material usage by 70%, this technology enables pharmaceutical companies to scale production efficiently and sustainably, meeting both industry needs and environmental demands.
“This funding is a pivotal milestone for PeptiSystems,” says Karin Granath, CEO of PeptiSystems. “It enables us to expand our production capacity, scale operations globally, and continue developing technologies that not only address growing demand but also align with the industry’s drive for sustainability and innovation. We are grateful for the strong support from our investors and excited to embark on this next phase of growth.”
“Peptide and oligonucleotide drugs are undergoing a transformation, with an increasing number of candidates targeting common diseases like type 2 diabetes and cancer. This development drives demand for more efficient manufacturing solutions. For peptides, PeptiSystems’ technology is a breakthrough that addresses bottlenecks in the process and enables faster drug development,” says Andreas Lindblom, Managing Partner at Sciety. “We are proud to support their continued growth and look forward to seeing their solutions set new standards for efficiency and sustainability in pharmaceutical manufacturing.”
Since launching its products in 2021, PeptiSystems has seen strong market traction. In 2023, the company generated SEK 33 million in revenue, a significant increase from SEK 9.8 million in 2022. PeptiSystems’ customer base spans the US, Europe, and Asia, including clients like Corden Pharma, a leading CDMO with over 450 global customers. With this investment, PeptiSystems is well-positioned to further strengthen its presence in key markets and continue addressing the growing global demand for peptide and oligonucleotide drugs.
Click to read more funding news.
Read the orginal article: https://arcticstartup.com/peptisystems-raises-e3-92m/
